Postmarketing non-interventional safety study on medicinal products containing aromatase inhibitors, Anastrozol Actavis 1 mg, Exemestan Actavis 25 mg, Trozara 2,5 mg

Study identification

• EU PAS number:
  EUPAS11481
• Study ID:
  11482
• Official title and acronym:
  Postmarketing non-interventional safety study on medicinal products containing aromatase inhibitors, Anastrozol Actavis 1 mg, Exemestan Actavis 25 mg, Trozara 2,5 mg
• DARWIN EU® study:
  No
• Study countries:
  Czechia
• Study description:
  PASS searching and collecting reports on adverse drug reaction, possibility of follow-up of the development of the clinical status of a patient and analyze reports.
• Study status:
  Planned

Research institutions and networks

Institutions

Actavis

Study timelines

Date when funding contract was signed

Planned: 14/04/2014

Study start date

Planned: 16/05/2014

Data analysis start date

Planned: 30/04/2017

Date of final study report

Planned: 28/02/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Actavis

Regulatory

• Was the study required by a regulatory body?:
  No